Stelfonta is a cancer veterinary medicine used in dogs to treat mast cell tumours that are not suitable for surgery and that have not spread to other parts of the body. These tumours are a type of cancer involving mast cells. These are immune system cells, found in many tissues, that release substances such as histamine. Stelfonta is used for mast cell tumours in the skin, or in mast cell tumours in the tissues just under the skin at or below the elbow or hock. Stelfonta contains the active substance tigilanol tiglate. How is Stelfonta used?
Stelfonta : EPAR - Medicine overview (PDF/120.43 KB)
First published: 11/02/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
QBiotics Netherlands B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
Prinses Margrietplantsoen 33
30/04/2020 Stelfonta - EMEA/V/C/005018 - IB/0002
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
For the treatment of non-resectable, non-metastatic (WHO staging) subcutaneous mast cell tumours located at or distal to the elbow or the hock, and non-resectable, non metastatic cutaneous mast cell tumours in dogs.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 18-19 January 202221/01/2022
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 13-15 July 202116/07/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 19-20 January 202122/01/2021